Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer


Alkermes plc ALKS presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC).

  • The data were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium.
  • The presentation includes updated efficacy and safety data from the monotherapy arm of ARTISTRY-1, in which anti-tumor activity was observed in RCC patients, including patients who were checkpoint inhibitor (CPI)-pretreated.
  • Yesterday, the Company reported better than expected Q4 FY21 financial results.
  • The ARTISTRY-1 monotherapy RCC cohort included 27 patients with advanced RCC, 56% of whom were CPI-pretreated. 
  • Nemvaleukin monotherapy induced robust expansion of CD8+ T and natural killer (NK) cells, with minimal effect on regulatory T cells (Tregs).
  • Among 23 evaluable patients, four patients achieved a partial response (one unconfirmed), and three of these patients continued on monotherapy.
  • Decreases in target lesions of up to 60% were observed. Stable disease was observed in 10 patients.
  • Regardless of causality, fever, chills, nausea, and anemia were the most frequently reported adverse events (AEs). There were no deaths due to treatment-related AEs. 
  • Price Action: ALKS shares are down 7.05% at $24.90 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsKidney CancerPhase 1 TrialPhase 2 Trialrenal cell carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!